

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Per Broberg et al.

Application No.: 10/572,872

Confirmation No.: 3651

Filed: March 21, 2006

Art Unit: 1652

For: ELASTIN PEPTIDE FINGERPRINTS AND  
ANALYSIS METHODS FOR MMP12  
RELATED TO COPD

---

Examiner: Rosanne Kosson

**APPEAL BRIEF**

MS Appeal Brief - Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

As required under § 41.37(a), this brief is filed within seven months of the Notice of Appeal filed in this case on September 21, 2010, and is in furtherance of said Notice of Appeal.

The fees required under § 41.20(b)(2) are dealt with in the accompanying  
TRANSMITTAL OF APPEAL BRIEF.

This brief contains items under the following headings as required by 37 C.F.R. § 41.37 and M.P.E.P. § 1205.2:

- |            |   |
|------------|---|
| I.         | Real Party In Interest                        |
| II         | Related Appeals and Interferences             |
| III.       | Status of Claims                              |
| IV.        | Status of Amendments                          |
| V.         | Summary of Claimed Subject Matter             |
| VI.        | Grounds of Rejection to be Reviewed on Appeal |
| VII.       | Argument                                      |
| VIII.      | Claims  |
| Appendix A | Claims  |
| Appendix B | Evidence                                      |
| Appendix C | Related Proceedings                           |

I. REAL PARTY IN INTEREST

The real party in interest for this appeal is:

AstraZeneca AB

II. RELATED APPEALS AND INTERFERENCES

There are no other appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in this appeal.

III. STATUS OF CLAIMS

Total Number of Claims in Application

There are 5 claims pending in the application.

Current Status of Claims

1. Claims canceled: 2 and 7-15

2. Claims withdrawn from consideration but not canceled: None

3. Claims pending: 1 and 3-6

4. Claims allowed: none

5. Claims rejected: 1 and 3-6

6. Claims objected to: none

Claims On Appeal

7. The claims on appeal are claims 1 and 3-6

(see Claims Appendix A)

1           IV.     STATUS OF AMENDMENTS

2           Applicants filed a Response to Final Office Action on September 21, 2010. The  
3 Examiner responded to the Response to Final Office Action with an Advisory Action mailed  
4 September 28, 2010. In the Advisory Action, the Examiner indicated that Applicants'  
5 amendments to the claims would be entered. Accordingly, the claims enclosed herein as  
6 Appendix A incorporate the amendments of the Amendment And Reply Under 37 CFR §1.116  
7 of September 21, 2010.

8           Applicants filed a Notice of Appeal on September 21, 2010.

9           V.     SUMMARY OF CLAIMED SUBJECT MATTER

10          Of the 5 claims on appeal, claims 1 and 5 are the only independent claims. The claims  
11 stand or fall together.

12          Claim 1 recites a set of purified peptides comprising peptide products resulting from the  
13 degradation of elastin by the enzyme matrix metalloproteinase 12 (MMP12), wherein the set of  
14 peptides comprises at least twenty of the peptides identified in Table 2. (page 15, lines 5-11;  
15 page 16, lines 16-28; page 24, lines 23-30; page 38, line 25 through page 40, line 21; Tables 1  
16 and 2).

17          Claim 5 recites a set of purified peptides comprising purified peptide products resulting  
18 from the degradation of elastin by the enzyme matrix metalloproteinase 12 (MMP12), wherein  
19 the set of peptides comprises all the peptides identified in Table 1. (page 15, lines 5-11; page 16,  
20 lines 16-28; page 24, lines 23-30; page 38, line 25 through page 40, line 21; Tables 1 and 2).

21          VI.    GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

22          1.     Claims 1 and 3-6 are rejected under 35 U.S.C. § 112, second paragraph as being  
23 indefinite.

24          VII.   ARGUMENT

25          A. The Invention

1        This application claims a set of purified peptides comprising peptide products resulting  
2        from the degradation of elastin by the enzyme matrix metalloproteinase 12 (MMP12). These  
3        purified peptides may be used as biomarkers for the diagnosis of diseases such as Chronic  
4        Obstructive Pulmonary Disease (COPD). Experiments in MMP12 knock-out mice strongly  
5        indicate that MMP12 is a key enzyme in COPD pathogenesis. MMP12 is believed to degrade  
6        lung tissue by degrading the elastin within the tissue. (See specification, page 8, lines 10-16).  
7        Therefore the elastin degradation products produced by MMP12 digestion can serve as markers  
8        of COPD.

9        The claimed peptides may also be used in drug discovery and development. At the time  
10       of Applicants' invention, the use of proteomics in drug discovery and development for COPD  
11       was limited by various factors, including the lack of profiles of disease-associated peptides that  
12       can be linked to specific drug targets, the lack of biomarkers to identify COPD sufferers at an  
13       early stage of the disease, and the lack of biomarkers to evaluate potential drugs that are MMP12  
14       inhibitors. (See specification, page 8, lines 23-31). The present invention provides a useful  
15       marker for identifying and evaluating MMP12 inhibitors.

16       B. 35 U.S.C. § 112 Rejection - Claims 1 and 3-6 are rejected under 35 U.S.C. § 112 as  
17       being indefinite

18       The Final Office Action on appeal ("the Office Action") alleges that the set of purified  
19       peptides identified in Table 1 or 2 of the specification are not physical peptides and that the  
20       Applicants have not made compositions comprising the peptides of Table 1 or 2. Applicants  
21       respectfully disagree.

22       "The requirement to 'distinctly' claim means that the claim must have a meaning  
23       discernible to one of ordinary skill in the art when construed according to correct principles.  
24       Only when a claim remains insolubly ambiguous without a discernible meaning after all  
25       reasonable attempts at construction must a court declare it indefinite." *Metabolite Labs., Inc. v.*  
26       *Lab. Corp. of Am. Holdings*, 370 F.3d 1354, 1366, 71 USPQ2d 1081, 1089 (Fed. Cir. 2004). As  
27       stated in § 2173.02 of the M.P.E.P. "[t]he test for definiteness under 35 U.S.C. 112, second  
28       paragraph, is whether 'those skilled in the art would understand what is claimed when the claim  
29       is read in light of the specification.'" (M.P.E.P. § 2173.02, emphasis added). If one skilled in

1 the art is able to ascertain the meaning of the terms in light of the specification, 35 U.S.C. 112,  
2 second paragraph, is satisfied. See M.P.E.P. § 2173.02.

3 Preparation of the claimed set of purified peptides is described in the specification, for  
4 example, at page 40, lines 6-21. Briefly, human lung elastin is used as the substrate in an *in vitro*  
5 assay reaction with human MMP12. Incubation was done at 37°C for 7 hours wherein the elastin  
6 was degraded by MMP12. A sample preparation step was performed using a reversed phase  
7 preparation step. The sample was eluted and run on the MALDI-TOF mass spectrometer where  
8 a peptide fingerprint of the MMP12/elastin degradation products was identified and annotated.  
9 Tables 1 and 2 show the MS atomic mass unit identities of elastin peptides resulting from  
10 MMP12 digestion and separation by column chromatography. (See specification, page 45, lines  
11 23-26).

12 Therefore a reading of the claims in light of the specification would indicate that the set  
13 of purified peptides identified in Table 1 or 2 of the specification are physical peptides and that  
14 the Applicants have made compositions comprising the peptides of Table 1 and 2.

15 The Office Action further alleges that some of the molecular weights listed in Table 1 or  
16 2 correspond to molecules that are fragments of the MMP12 digestion products produced by the  
17 ionization process in mass spec. Applicants respectfully disagree. The type of mass  
18 spectrometry used in the present invention, MALDI-TOF, does not create peptides, but rather  
19 ionizes existing peptides to allow their atomic mass to be measured. Therefore MALDI-TOF is a  
20 preferred method of peptide analysis because peptides tend to fragment when ionized by other  
21 ionization techniques (see page 1 of MALDI-TOF entry in ChemWiki: The Complete Chemistry  
22 Textbook, at [http://chemwiki.ucdavis.edu/Analytical\\_Chemistry/Instrumental\\_Analysis/MALDI-](http://chemwiki.ucdavis.edu/Analytical_Chemistry/Instrumental_Analysis/MALDI-TOF)  
23 TOF, submitted in the Response to Final Office Action filed September 21, 2010, copy attached).  
24 Furthermore, the Patent Office has failed to provide any evidence that the mass spec methods of  
25 the present invention would be expected to produce fragments of the MMP12 digestion products.

26 Moreover, the claims distinctly and definitely identify physical peptides by reciting both  
27 that the peptides are the degradation products of elastin and that they have a peptide mass  
28 identified in Table 1 or 2. There is no requirement that a peptide be identified by amino acid  
29 sequence. However, the amino acid sequence also is readily obtainable from the data provided.

1 From the known amino acid sequence of elastin, the amino acid sequences of the peptides  
2 listed in Tables 1 and 2 can be determined from the mass data using publicly available mass  
3 spectra sequence analysis algorithms. For example, the attached document entitled "Elastin  
4 Peptides" (submitted as Appendix A in the Response to Final Office Action filed September 21,  
5 2010) shows the amino acid sequences of the peptides of Table 1 determined from the peptide  
6 mass (observed mass) listed in Table 1 and the corresponding calculated mass determined by  
7 mass spectra sequence algorithms. The difference between the observed mass and calculated  
8 mass is less than 0.25 mass units for each peptide. Thus a person of ordinary skill in the art  
9 would recognize the subject matter claimed with the particularity and distinctness required by 35  
10 U.S.C. § 112.

11  
12 VIII. CLAIMS

13 A copy of the claims involved in the present appeal is attached hereto as Appendix A.  
14

15 The requisite fee for filing an Appeal Brief and the fee for a five-month extension of time  
16 are paid by credit card. If any additional fee is due, please charge our Deposit Account No. 03-  
17 2775, under Order No. 15652-10100 from which the undersigned is authorized to draw.

Dated: April 21, 2011

Respectfully submitted,

Electronic signature: /Joseph A. Ciardi/  
Joseph A. Ciardi

Registration No.: 64,760  
CONNOLLY BOVE LODGE & HUTZ LLP  
1007 North Orange Street  
P. O. Box 2207  
Wilmington, Delaware 19899-2207  
(302) 252-3628  
Agent for Applicant

#4298427\_1

**APPENDIX A**

**Claims Involved in the Appeal of Application Serial No. 10/572,872**

1. A set of purified peptides comprising peptide products resulting from the degradation of elastin by the enzyme matrix metalloproteinase 12 (MMP12), wherein the set of peptides comprises at least twenty of the peptides identified in Table 2.
2. (Canceled).
3. The set of purified peptides as claimed in claim 1 which comprises at least ninety of the peptides identified in Table 2.
4. The set of purified peptides as claimed in claim 1 which comprises at least one hundred and fifty of the peptides identified in Table 2.
5. A set of purified peptides comprising purified peptide products resulting from the degradation of elastin by the enzyme matrix metalloproteinase 12 (MMP12), wherein the set of peptides comprises all the peptides identified in Table 1.
6. The set of purified peptides as claimed in claim 1 which comprises all the peptides identified in Table 2.

**APPENDIX B**

Copies of the following documents are appended as evidence. They are listed in the order they were cited by Applicants in the Appeal Brief submitted herewith:

1. ChemWiki: The Complete Chemistry Textbook, at [http://chemwiki.ucdavis.edu/Analytical\\_Chemistry/Instrumental\\_Analysis/MALDI-TOF](http://chemwiki.ucdavis.edu/Analytical_Chemistry/Instrumental_Analysis/MALDI-TOF). This reference was submitted with the Response to Final Office Action filed September 21, 2010.
2. Elastin peptides. This reference was submitted as Appendix A with the Response to Final Office Action filed September 21, 2010.

1  
2  
3

**APPENDIX C**

None.

# MALDI-TOF

Proteins and peptides have been characterized by high pressure liquid chromatography (HPLC) or SDS PAGE by generating peptide maps. These peptide maps have been used as fingerprints of protein or as a tool to know the purity of a known protein in a known sample. Mass spectrometry gives a peptide map when proteins are digested with amino end specific, carboxy end specific, or amino acid specific digestive enzymes. This peptide map can be used to search a sequence database to find a good match from the existing database. This is because the more accurately the peptide masses are known, the less chance there is of bad matches.

Introduction .....	1
Schematic and Theory of MALDI .....	1
Sample preparation .....	2
Matrix .....	3
Sensitivity .....	3
Structural Information .....	3
TOF analyzer .....	4
Modes .....	4
References .....	6
Contributors .....	6

## Introduction

Electron spray ionization coupled to triple quadrupole (TSQ) and ion trap mass spectrometers (ITMS) and matrix assisted laser desorption ionization (MALDI) coupled to time of flight (TOF) analyzers have been successful for obtaining very accurate mass measurements. TOF, TSQ, and ITMS can give mass accuracies better than 0.1. MALDI-TOF mass spectra (MS) is a good tool for screening peptide masses of tryptic digests. This method is more effective because it requires relatively less intense sample preparation since the matrix is less susceptible to interferences caused by salts and detergents. Secondly MALDI-TOF-MS generates peptides containing only one charge and show only one peak in spectrum which facilitates data interpretation.

## Schematic and Theory of MALDI

MALDI is a very sensitive technique for determining the mass of proteins, peptides, or polymers. Protein masses are identity of proteins and thus help in proteomics. Thus MALDI allows protein identification. MALDI sample preparation is relatively fast and easy. It is a first choice when it comes to protein study. Proteins, peptides, and polymers are fragile and tend to fragment when ionized by other ionization techniques.

MALDI is attached to a time of flight (TOF) analyzer which measures time it takes for the molecules to travel a fixed distance. MALDI is a soft ionization technique in which a short laser pulse, instead of continuous laser, of nitrogen gas usually around 237 nm is used to ionize molecules. A protein or peptide sample is placed on a target plate and mixed with an appropriate matrix on the target plate. The mixture of sample and matrix crystallizes due to the vacuum environment and then is irradiated with a short laser pulse. The sample molecules and the matrix now enter gas phase. This leads to release of matrix, samples molecules, and ions from the target plate. The ions then accelerate in TOF analyzer because they are subject to equal electric field. TOF is a field-free flight tube. The ions travel in a straight and linear direction to the detector. The mass to charge ratio ( $m/z$ ) of the sample ions can be calculated using the equation  $T = C1(m/z)^{0.5} + C2$ .  $C1$  and  $C2$  are instrumental constants which can be determined with compounds of known mass. This equation is derived from the fact that potential energy equals kinetic energy.

$$KE = 0.5mv^2 \quad \text{eq. 1}$$

$$v = (2KE/m)^{1/2} \quad \text{eq. 2}$$

Since velocity is distance/time substitute it in eq. 2 and solve for  $t$  to get eq. 3

$$t = m^{1/2} * d / (2KE)^{1/2} \quad \text{eq.3}$$

The distance the molecules travel and their kinetic energy is constant. So it is replaced by  $C1$ . Furthermore since the relationship between the  $t$  and  $m^{1/2}$  is linear an intercept of  $C2$  is added to get equation of a line.

$$t = C1(m/z)^{1/2} + C2 \quad \text{eq.4}$$

## Sample preparation

Biomolecules such as proteins, peptides, sugars, and large organic molecules such as polymers, dendrimers and other macro molecules can be analyzed using MALDI. Sample preparation for MALDI is very simple; however, it is one of the most crucial steps in the MALDI analysis process. MALDI is more tolerant to sample contaminants, but contaminants can seriously disturb incorporation of sample molecules with growing matrix crystals. This results in bad spots on the target plate, leading to low signal to noise ratio, resolution, and sensitivity.

Samples can be prepared in two different ways. One removes the contaminants before applying them on to the matrix and one removes the contaminants after the sample is spotted on to the target plate either before or after adding the matrix.

Miniaturized chromatographic set-up is used for the first approach, while some scientists have cleaned in-gel digest of proteins using reverse phase(RP) HPLC microcolumns packed with different types of RP-HPLC beads (1). Now tips

are also packed with RP or ion-exchange resin to remove salts and detergents from protein mixtures, and their effectiveness is shown by their recent commercialization. Tips and columns effectively remove MALDI contaminants and give small volume of sample, this can result in possible highly sensitive MALDI analysis of the samples.

Purification of biological samples on target plates involves synthetic membranes or surfaces. Membranes go on top of the target plate and the biological samples are spotted on top of the membranes. Biological samples interact with the membrane through strong hydrophobic forces. This enables samples to remain on the membrane while the buffers and salts are washed away. Then the MALDI-matrix solution is added to the purified samples on the target plate, ready for analysis. Perfluorosulfonated ionomer films, polyethylene membranes, nonporous polyurethane membranes, and C8 and C18 extraction disks are examples of membranes that have been used successfully in the past for biological mixtures. Self-assembled monolayers (SAMs) of octadecyl mercaptan on gold-sputtered disposable MALDI probe tips have been used to concentrate the sample and to act as a purification device. However, it is unfeasible because it requires overnight sample incubation to fully concentrate at the probe tip.

## Matrix

The function of the matrix is adsorption of energy from laser pulse, and then transfer to sample“thereby causing desorption of the analyte molecules in an expanding plume, to ionize the desorbed analyte molecules and to prevent aggregation of the analyte molecules”(2). The matrix molecules for MALDI are chosen on the basis on fulfillment of requirement that matrix molecules must be able to absorb ultra violet wavelength of usually 237nm, low volatility and ability to transfer protons to the sample molecules. For proteins samples typical MALDI matrix consist of cinnamic acid and hydroxylated benzoic acid derivatives.

2,5-dihydroxybenzoic acid is more tolerant to the sample contaminants because it excludes them during crystallization process(3). The use of specially prepared thin matrix layers uses fast evaporation setup, which not only improves the sensitivity and resolution, but also allows the samples to be extensively washed, removing salts and detergents. Since the sensitivity depends on the concentration of the sample on the target plate, samples can be concentrated using PR-HPLC or bead-peptide concentration. In bead-peptide concentration RP-chromatographic beads are added to the proteins or peptide samples, and these samples preferentially bind to the beads through hydrophobic interactions while the contaminants like salts and chaotrophes do not. After a short incubation, the peptide-bead solution is harvested using pellets from a centrifugation, and dried in speed vacuum concentrator. In both cases, highly concentrated pellets of peptide-bound beads are obtained, which can be transferred to MALDI and left to dry. Because the beads are hydrophobic in nature, they form a cluster in highly concentrated spot ( $<1\text{mm}^2$ ) on MALDI target plate after drying. Peptides elute on the target plate by a small volume of aqueous/organic MALDI-matrix solution and become incorporated into the growing matrix crystals at the same time. This process allows 10 to 100 fmol to be enough to be loaded on to the gels.

## Sensitivity

Sensitivity of MALDI depends on sample preparation and the preparation of sample/matrix layer. They must be optimized by trial and error according to sample size, type, and previous history. Preparing a very thin matrix layer and applying of sample so that the sample is on the outer layer of matrix, give a sensitivity level of low attomole ( $10^{-18}$ ). This method makes it possible for “...removal of salts present in the analyte solution by a sample washing procedure away from the sample very simply” (4). Small matrix spots using nanoliter volumes of matrix and analyte solution, combined purification, concentration, and application procedures have also given similar sensitivities (5). In this method, matrix is adsorbed to nanoliter bed volume reversed-phase column prepared in an Eppendorf GeLoder tip. Then the column is washed and the sample is eluted with a few nanoliter volume of matrix onto the target plate.

Sensitivity is reduced with increasing molecular weight. The sensitivity is two to three magnitudes lower for proteins than it is for peptides. So the sensitivity of proteins is in the femtomole range.

## Structural Information

Structural information of proteins can be determined by digesting proteins with specific endoprotease like trypsin, AspN, and GluC. MALDI is one of the best spectrometric techniques for direct analysis of peptide mixtures. Signals of peptides are suppressed because there is a competition for charge or optimal position in the matrix. Therefore signal intensity does not necessarily reflect the quantities of different peptides in the mixtures. Complete sequences can be obtained from a combination of spectra recorded in different modes, like positive and negative, matrices, and different enzyme digestion.

Sequence information is also possible to get from PSD. This is possible by controlling the voltage of the reflector, which results in different  $m/z$  ranges on the detector and generates a PSD spectrum. A large sample amount is required since only a small fraction goes under PSD. Additionally, the fragmentation can not be controlled since different site of a peptide can get fragmented. This makes it very hard to get complete sequences of a peptide. Alternatively, collision cells are included to the flight tube in MALDI-TOF by some manufacturers, to have controlled fragmentation by collision-induced dissociation.

Large amounts of in-source fragmentation occurs before initiation of the acceleration voltage called in-source decay in delayed extraction equipped MALDI-TOF, which only yield long regions of sequence-specific ions (6). C-terminal sequence ladders can be generated by digestion of peptides with carboxypepsidase and N-terminal sequence ladders can be obtained by Edman degradation using low percentage of phenylthiocarbamate rather than phenylisothiocarbamate in the coupling reaction. These ladders in the mixtures of peptides can be an alternative to sequence-specific fragment ions. This process often gives a lot of sequence information.

Secondary protein modifications can also be determined using MALDI-TOF-MS. The steps involved in determining secondary modifications are measuring mass of the intact protein, knowing the protein's primary sequence, and generating site-specific information by direct mass spectrometric peptide mapping of a mixture derived by proteolytic cleavage of the proteins. In tandem (TOF/TOF) configurations, MALDI instruments can provide protein sequence data, as well.


In tandem mass spectrometry, an ion of a particular mass is selected (that's the first stage of the analysis) and fragmented. Its constituent fragment ions are then mass-analyzed a second time (that's the tandem stage) to reveal data about the molecule's structure or sequence; single-stage TOF instruments lack this capability (though some fragmentation does occur via "post-source decay" as the ions traverse the flight tube).

Some companies offer tandem MALDI instruments based on hybrid mass analyzer configurations. Applied Biosystems' QSTAR, for instance, couples an optional MALDI source with a quadrupole-time-of-flight mass analyzer, as does Waters Corporation's MALDI Q-Tof Premier.

## TOF analyzer

### Modes

Ions can travel in a linear fashion and be detected by the detector at the opposite end as an ion source. This is called linear TOF. It is different from a reflectron TOF, in which ions are reflected to electrostatic mirror and detected by another detector. Linear TOF spectrum is limited in resolution leading to low mass accuracy. This is because initially different amount of kinetic energy can be attained by the ions with the same charge. This leads to different ( $m/z$ ) ratio of ions which have different initial velocities. This is partially corrected by reflectron TOF. High energy ions penetrate deeper into the reflectron, taking longer distance and time, while low energy ions do not penetrate as deep into the reflectron and take a shorter path and time. This leads to correction of different times of ions with the same mass and charge. This leads to an increase of resolution to 10,000.



The amount of energy put into ions by the laser initially can also be corrected by a technique called delayed extraction (DE) in which acceleration voltage is applied slightly after the laser pulse. DE TOF increases resolution to 2000.

RE TOF can give full isotopic resolution for molecules up to 15 kDa. However  $^{12}\text{C}$ -only ion peak will have very low intensity for molecules bigger than 5 kDa. Resolution is further decreased because each ion decays after acceleration and its time of flight can not be adjusted by RE TOF because decay has already occurred. These ions are not detected in RE TOF. However, these ions can be detected in linear TOF, but resolution still decreases because linear TOF has no way of correcting different energy inputs to an ion with the same mass and charge. It is better to use linear mode to get spectra and determine isotopically averaged mass for molecules bigger than 5-10 kDa. Resolution depends on the size of the molecules in a sample. The greater the size that the sample molecule has, the lower the resolution of it.

MALDI-TOF can only be compared to ESI because they are two ways of directly analyzing proteins, peptides, and polymers. MALDI-TOF samples can be reanalyzed while ESI samples can not because ESI is connected to LC column, and the analysis is limited to the width of the chromatographic peak. MALDI-TOF can scan 10 spectra for a peak 10 seconds wide per second, while it takes ESI almost 15 second. MALDI-TOF-MS generates mostly ions  $\pm 1$  charge while ESI generates a charge for every 8-10 amino acids. That means ESI spectra are considerably more complex than MALDI spectra. Coulombic repulsion increases as the charge increase, leading to data deviation, and in MALDI

spectra, this repulsion does not occur. However, multiple charges in ESI give better resolution because the higher the mass to charge ratio, the harder it is to get good resolution. In general MALDI is faster than ESI, and enables higher throughput. But ESI is more sensitive.

### References

1. Proteomics in functional genomics : protein structure analysis / edited by P. Jollès and H. Jörnva
2. Fey SJ et al. (1997) Proteome analysis of *Saccharomyces cerevisiae*: A methodological outline. *Electrophoresis* 18: 1361-1372
2. Karas M. et al. (1998) Laser desorption ionization of proteins with molecular mass exceeding 10,000 daltons. *Anal Chem* 60: 2299-2301
3. Patterson SD, Aebersold R (1995) Mass spectrometric approaches for the identification of gel-separated proteins. *Electrophoresis* 16: 1791-1814
4. Vorm O, Roepstroff P, Mann M (1994) Improved resolution and very high sensitivity in MALDI-TOF of matrix surfaces made by fast evaporation. *Anal Chem* 66: 3281-3287
5. Jespersen S, Niessen WM, et al. (1994) Attomole detection of proteins by matrix assisted laser desorption/ionization mass spectrometry with the use of picoliter vials. *Rapid Comm. Mass Spectrom* 8: 581-584
6. Reiber DC, Grower TA, et al. (1998) Identifying proteins and matrix-assisted laser desorption/ionization in source fragmentation data combined with database searching. *Anal Chem* 70: 673-678

### Contributors

- Basir Syed

## Elastin Peptides

Human elastin protein reference sequence registered on public repository as UniProtKB/Swiss-Prot  
P15502 (ELN\_HUMAN)

aa position	sequence				
1	MAGLTAAAPR	PGVLLLLLSI	LHPSRPGGVP	GAIPGGVPGG	VFYPGAGLGA
51	LGGGALGPGG	KPLKPVPGGL	AGAGLGAGLG	AFPAVTFGA	LVPGGVADAA
101	AAYKAAKAGA	GLGGVPGVGG	LGVSAAGAVP	QPGAGVKPGK	VPGVGLPGVY
151	PGGVLPGARF	PGVGVLPGVP	TGAGVKPKAP	GVGGAFAGIP	GVGPFGGPQP
201	GVPLGYPIKA	PKLPGGYGLP	YTTGKLPYGY	GPGGVAGAAG	KAGYPTGTGV
251	GPQAAAAAAA	KAAAKFGAGA	AGVLPGVGGA	GVPGVPGAIP	GIGGIAGVGT
301	PAAAAA	AKAAKYGAAA	GLVPGGPGFG	PGVVGVPAG	VPGVGVPAG
351	IPVVPGAQIP	GAAVPGVVSP	EAAAKAAKA	AKYGARPGVG	VGGIPTYGVG
401	AGGFPGFGVG	VGGIPGVAGV	PSVGGVPGVG	GVPGVGISPE	AQAAAAKAA
451	KYGAAGAGVL	GGLVPGPQAA	VPGVPGTGGV	PGVGTAAAA	AKAAAKAAQF
501	GLVPGVGAP	GVGVAPGVGV	APGVGLAPGV	GVAPGVGVAP	GVGVAPGIGP
551	GGVAAAAKSA	AKVAAKAQLR	AAAGLGAGIP	GLGVGVGVPG	LGVGAGVPGL
601	GVGAGVPGFG	AGADEGVRRS	LSPELREGDP	SSSQHLPSTP	SSPRVPGALA
651	AKAAKYGAA	VPGVLGGLGA	LGGVGIPGGV	VGAGFAAAAA	AKAAAKAAQ
701	FGLVGAAGLG	GLGVGGLGVP	GVGGLGGIPP	AAAAKAAKYG	AAGLGGVLGG
751	AGQFPLGGVA	ARPGFGLSPI	FPGGACLGKA	CGRKRK	

# Elastin Peptides

peptide number	observed mass	calculated mass	Sequence and (adjacent aa)	position in P15502
1	772.4	772.3836	(V)GISPEAQA(A)	436-443
2	798.4	798.4104	(V)GPQAAAAAAA(K)	250-260
3	802.4	802.4166	(G)ADEGVRR(S)	611-619
4	817.5	817.4203	(L)GVGAGVPGFG(A)	601-610
5	823.4	823.3985	(K)LPYGYGPG(G)	225-233
6	824.4	824.3937	(P)GGVFYPGAG(L)	39-47
7	865.4	865.4050	(P)GGVADAAAAY(K)	91-100
8	874.6	874.5033	(P)AVTFPGALV(P)	84-92
9	878.5	878.5094	(A)KAAKYGAAPV(P)	653-661
10	904.4	904.4887	(K)AAKYGAAPVG(V)	654-663
11	937.5	937.5102	(A)PGIGPGGVAAAA(A)	546-557
12	944.5	944.5200	(A)AQFGLVPGVG(V)	49-507
13	951.5	951.4934	(G)KLPYGYGPG(G)	225-233
14	977.5	977.5091	(G)AFPAVTFPGA(L)	81-90
15	1027.5	1027.5531	(I)GPGGVAAAAKSAA(K)	548-561
16	1072.6	1072.5898	(A)GQFPLGGVAAR(P)	751-760
17	1073.6	1073.5990	(G)LGAGLGAFPAVT(F)	78-86
18	1089.5	1089.5647	(G)ADEGVRRSLS(P)	611-622
19	1094.6	1094.5840	(G)VPGTGGVPGVGT(P)	474-486
20	1107.6	1107.6157	(A)AGVLPVGGGAGVPG(V)	271-284
21	1114.6	1114.6255	(K)AAQFGLVPGVGV(A)	497-508
22	1137.6	1137.5899	(V)PGTGGVPGVGTAA(A)	472-487
23	1141.6	1141.5848	(P)GVGISPEAQAAAA(A)	433-446
24	1142.6	1142.6800	(P)TGTGVGPQAAAAAA(A)	246-259
25	1145.6	1145.5990	(R)PGFGLSPIFPGG(A)	763-774
26	1156.6	1155.6004	(G)VGISPEAQAAAA(K)	431-447
27	1171.6	1171.6000	(G)LAGAGLGAGLGAFP(A)	69-83
28	1185.7	1185.6950	(G)GVAAAAKSAAKVAA(K)	552-565
29	1193.6	1193.6000	(L)PYGYGPGGVAGAAG(K)	227-240
30	1199.6	1199.5903	(R)SLSPELREGDP(S)	620-630
31	1216.6	1216.5705	(G)AGVPGFGAGAD(Acetohydrazide)E(Acetohydrazide)G(V)	604-616
32	1232.6	1232.627	(V)PGGVADAAAAYKAA(K)	93-106
33	1237.6	1237.6535	(G)GVPGVGVISPE(Acetohydrazide)AQA(A)	431-443
34	1242.7	1242.6913	(V)RRSLSPELRE(G)	618-627
35	1254.7	1254.6841	(G)AGVPGLGVGAGVPGF(G)	595-609
36	1255.9	1255.7167	(G)AGVKPKAPGVGGAF(A)	173-186
37	1262.6	1262.6528	(I)PGVGPFGGPQPGVP(L)	190-203
38	1265.7	1265.6848	(L)GVSAGAVPQPGAGV(K)	122-138
39	1285.7	1285.6899	(V)PGGLAGAGLGAGLGAF(P)	67-82
40	1287.7	1287.7056	(A)AQFGLVGAAGLGGLG(V)	699-713
41	1291.7	1291.7005	(A)GVPSVGGVPGVGGVPG(V)	419-434
42	1296.7	1296.6906	(I)GGIAGVGTPAAAAAAA(A)	293-309
43	1298.7	1298.6964	(L)HPSRPGGVPGAIPG(G)	22-35
44	1299.7	1299.7056	(K)AAKYGAAAGLVPGGP(G)	313-327
45	1314.7	1314.7165	(I)PPAAAAKAAKYGAAG(L)	729-743
46	1320.8	1320.811	(S)PRVPGALAAAKAAK(Y)	643-656
47	1322.7	1322.7427	(G)VPGVGTAAAAAKAA(K)	480-495

# Elastin Peptides

48	1331.7	1331.6954	(L)VPGGVADAAAAAYKAA(K)	92-106
49	1347.7	1347.7056	(G)VGAGGFPGFGVGVGGI(P)	399-414
50	1362.7	1362.6593	(P)YGYGPGGVAGAAGKAG(Y)	228-243
51	1363.7	1363.7005	(G)GVFYFPGAGLGALGGGA(L)	40-55
52	1368.8	1368.7998	(G)VKPKAPGVGGAFAGI(P)	175-189
53	1369.0	1368.7998	(G)VKPKAPGVGGAFAGI(P)	175-189
54	1370.7	1370.7314	(P)AVTFPGALVPGGVAD(A)	84-98
55	1379.6	1379.7641	(L)GGLVGGGLGVPGVGGGLGG(I)	710-727
56	1402.8	1402.8053	(G)AGVPGVPGAIPGIGGIA(G)	280-296
57	1424.8	1424.822	(P)GIGPGGVAAAAKSAKV(A)	547-563
58	1440.7	1440.7958	(T)GAGVKPKAPGVGGAFAG(I)	172-189
59	1455.8	1455.8027	(E)GVRRLSPPELREG(D)	616-628
60	1469.8	1469.8111	(G)LGGVLGGAGQFPLGGVA(A)	744-760
61	1477.8	1477.8122	(I)PGGVVGAGPAAAAAAKAA(A)	677-696
62	1484.8	1484.822	(I)PPAAAAKAAKYGAAGLG(G)	629-645
63	1505.8	1505.7958	(V)GGVPGVGGVPGVGISPEA(Q)	424-421
64	1508.9	1505.8798	(P)GVGGGLGGIPPAKAAK(Y)	721-738
65	1519.8	1519.8115	(P)GAGIPGAAPGVVSPPEAA(A)	356-373
66	1520.8	1520.8067	(P)QAAVPGVPGTGGVPGVGT(P)	468-485
67	1524.8	1524.8169	(L)GVGAGVPGLVGVGAGVPGFG(A)	591-610
68	1536.8	1536.8016	(P)GVGGVPGVGISPEAQAAA(A)	428-445
69	1542.8	1542.8387	(V)GPQAAAAAAKAAKFGA(G)	251-268
70	1570.7	1570.8296	(E)GVRRLSPPELREGD(P)	616-629
71	1596.8	1596.8897	(G)LPGVYPGGVLPGARFP(G)	146-161
72	1599.8	1599.8602	(V)GPQAAAAAAKAAKFGAG(A)	251-269
73	1613.9	1613.901	(A)PGVGVAPGVGVAPGIGPGGV(A)	534-553
74	1644.8	1644.834	(P)GGVAGAAGKAGYPTGTGVGP(Q)	233-252
75	1666.9	1666.8911	(F)YFPGAGLGALGGGALGPGGKP(L)	43-62
76	1670.9	1670.9013	(G)QFPLGGVAARPGFGLSP(I)	752-769
77	1687.9	1687.9014	(V)PGAGIPGAAPGVVSPPEAA(K) 0	355-374
78	1696.9	1696.8945	(K)LPGGYGLPYTTGKLPY(G)	213-228
79	1702.2	1702.001	(G)VPGVGGGLGGIPPAKAAK(Y)	719-738
80	1706.8	1706.8424	(P)GGYGLPYTTGKLPYGY(G)	216-230
81	1718.9	1718.9072	(G)GVPGVGGVPGVGISPEAQAA(A)	425-444
82	1758.9	1758.8882	(G)VGAGVPGFGAGADEGVRRS(L)	602-620
83	1762.9	1762.985	(K)AAQFGLVPGVGVAPGVGVAP(G)	497-516
84	1763.9	1763.8639	(P)GGYGLPYTTGKLPYGY(G)	215-231
85	1770.0	1770.0021	(A)AKAAKYGARPGVGVGGIPT(Y)	378-396
86	1832.9	1833.0229	(I)PGAAPGVVSPPEAAKAAK(A)	360-380
87	1840.0	1840.0000	(A)AAAAKAAKYGAAAGLVPGGPG(F)	307-328
88	1851.0	1850.9912	(S)RPGGVPGAIPGGVPGGVFYF(G)	25-44
89	1885.0	1884.9967	(Y)GVGAGGFPGFGVGVGGIPGVAGV(P)	398-420
90	1920.0	1920.0338	(V)PGLGVGAGVPGLVGAGVPGFGAG(A)	589-612
91	1929.8	1930.0181	(P)GGVFYFPGAGLGALGGGALGPGGK(P)	39-61
92	1942.0	1942.0294	(L)GGVLGGAGQFPLGGVAARPGFG(L)	745-766
93	1998.1	1998.092	(G)LGGVLGGAGQFPLGGVAARPGF(G)	745-765
94	2168.1	2168.069	(F)GAGADEGVRRSLSPPELREGDP(S)	610-630
95	2367.2	2367.188	(K)YGARPGVGVGGIPTYGVGAGGFPGFG(V)	383-408
96	2620.3	2620.3074	(D)EGVRRSLSPPELREGDPSSSQHLP(S)	615-638
97	2823.5	2823.5304	(A)GLGGVLGGAGQFPLGGVAARPGFGLSPIFG(G)	743-773